Courtesy of SBHCI.
This new device has, on one hand, an abluminal sirolimus coating, and on the other hand, a luminal CD34 antibody coating for EPC capturing, to potentially accelerate post-PCI reendothelization.
Between 2014 and 2016, the study included 1496 patients undergoing acute coronary syndrome (ACS), receiving the new COMBO stent. These patients were randomized to 3 and 12 months of dual APT. Primary end point was a composite of death, infarction, stent thrombosis, stroke, revascularization and bleeding at 12 months.
Read also: “TCT 2017 | INTREPID: Mitral Replacement with a Self-Expanding Device”.
There were no differences in events between months 3 and 12 of DAPT (8.2% vs 8.4%, for non-inferiority < 0.001). There were no differences in major bleeding (2.5% vs 3%), death (1.9% vs 0.8%) or definite/probable thrombosis (1.2% vs 0.4%). However, the study did not have enough statistical power to assess these events separately.
Conclusion
The REDUCE study showed that 3 months DAPT are non-inferior to 12 months DAPT in ACS patients treated with the COMBO stent.
Courtesy of SBHCI.
Original title: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES With a Luminal CD34+ Antibody Coating in Patients With ACS.
Presenter: Harry Suryapranata.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.